Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer

Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast... Background CD44 and aldehyde dehydrogenase 1 (ALDH1) has been reputed to be cancer stem cell (CSC) markers in breast cancer. Yet, the clinicopathologic and prognostic significance of these markers remain unclear. In this study, we have investigated the expression of these markers and their relation with conventional clinicopathologic tumor characteristic including molecular subtype. Methods CD44 and ALDH1 expression were investigated by immunohistochemistry in a series of 157 formalin-fixed paraffin-embedded breast cancer tissues. Results Overall, CD44 and ALDH1 are, respectively, detected in 33% (52 of 157) and 7% (10 of 157) of breast cancer cases. We also observed that CD44 expression was associated with histological grade (p = 0.005). For ALDH1, we found that its expression is more frequent with elderly women (> 50 years, p = 0.03). The investigation of relationship between the stem cell phenotype and breast cancer molecular subtype, revealed that CD44 and ALDH1 expression was more frequent in basal-like tumors (p = 0.005). Among the two cancer stem cell markers tested, ALDH1 showed a strong association with the basal marker EGFR (p = 0.05). Conclusions These findings suggest that CD44 and ALDH1 play a role in the clinical behavior in breast cancer and might be interesting http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Springer Journals

Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/clinicopathological-significance-of-cancer-stem-cell-markers-cd44-and-BzAPga4LqW
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Japanese Breast Cancer Society
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery; Cancer Research
ISSN
1340-6868
eISSN
1880-4233
DOI
10.1007/s12282-018-0875-3
Publisher site
See Article on Publisher Site

Abstract

Background CD44 and aldehyde dehydrogenase 1 (ALDH1) has been reputed to be cancer stem cell (CSC) markers in breast cancer. Yet, the clinicopathologic and prognostic significance of these markers remain unclear. In this study, we have investigated the expression of these markers and their relation with conventional clinicopathologic tumor characteristic including molecular subtype. Methods CD44 and ALDH1 expression were investigated by immunohistochemistry in a series of 157 formalin-fixed paraffin-embedded breast cancer tissues. Results Overall, CD44 and ALDH1 are, respectively, detected in 33% (52 of 157) and 7% (10 of 157) of breast cancer cases. We also observed that CD44 expression was associated with histological grade (p = 0.005). For ALDH1, we found that its expression is more frequent with elderly women (> 50 years, p = 0.03). The investigation of relationship between the stem cell phenotype and breast cancer molecular subtype, revealed that CD44 and ALDH1 expression was more frequent in basal-like tumors (p = 0.005). Among the two cancer stem cell markers tested, ALDH1 showed a strong association with the basal marker EGFR (p = 0.05). Conclusions These findings suggest that CD44 and ALDH1 play a role in the clinical behavior in breast cancer and might be interesting

Journal

Breast Cancer – Springer Journals

Published: May 29, 2018

References

  • Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques; Soerjomataram, Isabelle; Dikshit, Rajesh; Eser, Sultan; Mathers, Colin; Rebelo, Marise; Parkin, Donald Maxwell; Forman, David; Bray, Freddie
  • Breast tumors heterogeneity: cancer stem cells or clonal evolution
    Campbell, LL; Polyak, K
  • The CD44+/CD24 phenotype is enriched in basal-like breast tumors
    Honeth, G; Bendahl, PO; Ringner, M; Saal, LH; Gruvberger-Saal, SK; Lovgren, K
  • Cancer stem cells in Breast cancer and metastases
    Lawson, JC; Blatch, GL; Edkins, AL
  • Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
    Ricardo, S; Vieira, AF; Gerhard, R; Leitao, D; Pinto, R; Cameselle-Teijeiro, JF
  • CD44, a therapeutic target for metastasin tumors
    Orian-Rousseau, V
  • Hyaluronan–CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion
    Bourguignon, LYW; Wong, G; Earle, C; Krueger, K; Spevak, CC
  • CD44 splice isoform switching in human and mouse epithelium is essential for epithelial–mesenchymal transition and breast cancer progression
    Brown, RL; Reinke, LM; Damerow, MS; Perez, D; Chodosh, LA; Yang, J
  • The properties of a mammary gland cancer stem cell
    Zucchi, I; Sanzone, S; Astigiano, S; Pelucchi, P; Scotti, M; Valsecchi, V
  • Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells
    Chute, JP; Muramoto, GG; Whitesides, J; Colvin, M; Safi, R; Chao, NJ
  • Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity
    Povsic, TJ; Zavodni, KL; Kelly, FL; Zhu, S; Goldschmidt-Clermont, PJ; Dong, C
  • Breast cancer cells lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Charafe-Jauffret, E; Ginestier, C; Iovino, F; Wicinski, J; Cervera, N; Finetti, P
  • Tumor-endothelial interaction links the CD44(+)/CD24(–) phenotype with poor prognosis in early-stage breast cancer
    Buess, M; Rajski, M; Vogel-Durrer, BM; Herrmann, R; Rochlitz, C
  • The clinicopathologic and prognostic significance of CD44+/CD24–/low and CD44–/CD24 + tumor cells in invasive breast carcinomas
    Mylona, E; Giannopoulou, I; Fasomytakis, E; Nomikos, A; Magkou, C; Bakarakos, P
  • Prevalence of CD44+/CD24–/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis
    Abraham, BK; Fritz, P; McClellan, M; Hauptvogel, P; Athelogou, M; Brauch, H
  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer
    Goldhirsch, A; Winer, EP; Coates, AS; Gelber, RD; Piccart-Gebhart, M; Thürlimann, B
  • ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome
    Tan, EY; Thike, AA; Tan, PH
  • In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis
    Neumeister, V; Agarwal, S; Bordeaux, J; Camp, RL; Rimm, DL
  • Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1–3 lymph node metastases
    Nogami, T; Shien, T; Tanaka, T; Nishiyama, K; Mizoo, T; Iwamto, T
  • Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer
    Sakakibara, M; Fujimori, T; Miyoshi, T; Nagashima, T; Fujimoto, H; Suzuki, HT
  • The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis
    Dong, Y; Bi, LR; Xu, N; Yang, HM; Zhang, HT; Ding, Y
  • Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor positive human epidermal growth factor receptor type 2, and high Ki67 expression
    Morimoto, K; Kim, SJ; Tanei, T; Shimazu, K; Tanji, Y; Taguchi, T
  • The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast CD44/CD24 expression in breast cancer
    Kapucuoglu, N; Bozkurt, KK; Baspınar, S; Kocer, M; Eroglu, HE; Akdeniz, R
  • Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer
    Tsang, JYS; Huang, YH; Luo, MH; Ni, YB; Chan, SK; Lui, PCW
  • CD44+/CD24 markers of cancer stem cells in patients with Breast cancer of different molecular subtypes
    Chekhun, SV; Zadvorny, TV; Tymovska, YO; Anikusko, MF; Novak, OE; Polishchuk, LZ
  • Expression of cancer stem cell markers in basal and penta-negative breast carcinomas—a study of a series of triple-negative tumors
    Uchoa, DM; Graudenz, MS; Callegari-Jacques, SM; Hartmann, CR; Ferreira, BP; Fitarelli-Kiehl, M
  • Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target
    Yan, Y; Zuo, X; Wei, D
  • Expression distribution of cancer stem cells, epithelial to mesenchymal transition, and telomerase activity in breast cancer and their association with clinicopathologic characteristics
    Makki, J; Myint, O; Wynn, AA; Samsudin, AT; John, DV
  • Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression
    Kim, YS; Jung, MJ; Ryu, DW; Lee, CH
  • CD44+/CD24 cancer stem: progenitor cells are more abundant in triple-negative invasisve breast carcinoma phenotype and are associated with poor outcome
    Idowu, MO; Kimeciak, M; Dumu, C; Burton, RS; Grimes, MM; Powers, CN
  • Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types
    Beça, FF; Caetano, P; Gerhard, R; Alvarenga, CA; Gomes, M; Paredes, J
  • Breast cancer stem:progenitor cells and estrogen receptor
    Dontu, G; El-Ashry, D; Wisha, MS
  • BRCA1 regulates human mammary stem:progenitor cell fate
    Liu, S; Ginestier, C; Charafe-Jauffret, E; Focco, H; Kleer, CG; Merajver, SD
  • Hallmarks of “BRCAness” in sporadic cancers
    Turner, N; Tutt, A; Ashworth, A
  • Therapeutic implications of cancer stem cells
    Al-Hajj, M; Becker, MW; Wicha, M; Weissman, I; Clarke, MF
  • CD44 as a drug delivery target in human cancers: where are we now?
    Sahin, IH; Klostergaard, J